had diabetes mellitus or not, closer to or at the time of diagnosis would have improved our study and reduced misclassification. This would, however, reduce nondifferential misclassification, and this should rather strengthen than weaken the report on associations.
All participants in the HUNT study are identified with an eleven-digit national identification number that all Norwegians are given at birth or immigration. All data regarding HUNT participants are linked by this key, and no duplicate data set are present in the HUNT database.
Diabetes mellitus was no exclusion criteria in the pemetrexed-gemcitabine study or in the Norwegian Lung Cancer Biobank (Norwegian Lung Cancer Biobank study, and the prevalence of diabetes mellitus was 3.9% (mean age 64 years) and 8.1% (mean age 68 years), respectively. Therefore, we have no indication of diabetes mellitus being the cause of any selection bias in the PEG or NLCB study. In these studies, we used the medical journal to identify whether patients had diabetes mellitus or not. 5%) had diabetes mellitus; so this ratio was apparently lower than the prevalence of diabetes mellitus in developed countries. 3 In their study, patients with diabetes mellitus were defined as those who answered that they had diabetes mellitus and those who used medication for the same. We would like to know from the authors about whether that was appropriate. Two -thirds of their patients were participants in the Nord-Trøndelag Health Study (HUNT), a population-based prospective cohort study started in 1984. However, median survivals of the patients with diabetes mellitus in the HUNT study were very short (8 and 6 months); this contrasts with the median survivals in the present-day situation, as treatments for diabetes mellitus have progressed a lot during the last two decades. Therefore, we wonder whether the study included old data. Because the periods of the Nord-Trøndelag Disclosure: The authors declare no conflict of interest.
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